Abstract
Objective: External fistulas represent a disabling manifestation of Crohn's disease with a difficult curability and a high relapse rate despite a large therapeutic armamentarium. Stem cell therapy is a novel and promising approach for treatment of chronic inflammatory conditions. We therefore investigated the feasibility, safety and efficacy of serial intrafistular injections of autologous bone marrow-derived mesenchymal stromal cells (MSCs) in the treatment of fistulising Crohn's disease. Patients and methods: We enrolled 12 consecutive outpatients (eight males, median age 32 years) refractory to or unsuitable for current available therapies. MSCs were isolated from bone marrow and expanded ex vivo to be used for both therapeutic and experimental purposes. Ten patients (two refused) received intrafistular MSC injections (median 4) scheduled every 4 weeks, and were monitored by surgical, MRI and endoscopic evaluation for 12 months afterwards. The feasibility of obtaining at least 50×106 MSCs from each patient, the appearance of adverse events, and the efficacy in terms of fistula healing and reduction of both Crohn's disease and perianal disease activity indexes were evaluated. In addition, the percentage of both mucosal and circulating regulatory T cells expressing FoxP3, and the ability of MSCs to influence mucosal T cell apoptosis were investigated. Results: MSC expansion was successful in all cases; sustained complete closure (seven cases) or incomplete closure (three cases) of fistula tracks with a parallel reduction of Crohn's disease and perianal disease activity indexes (p
| Original language | English |
|---|---|
| Pages (from-to) | 788-798 |
| Number of pages | 11 |
| Journal | Gut |
| Volume | 60 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Jun 2011 |
Fingerprint
ASJC Scopus subject areas
- Gastroenterology
Cite this
Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. / Ciccocioppo, Rachele; Bernardo, Maria Ester; Sgarella, Adele; Maccario, Rita; Avanzini, Maria Antonietta; Ubezio, Cristina; Minelli, Antonella; Alvisi, Costanza; Vanoli, Alessandro; Calliada, Fabrizio; Dionigi, Paolo; Perotti, Cesare; Locatelli, Franco; Corazza, Gino Roberto.
In: Gut, Vol. 60, No. 6, 06.2011, p. 788-798.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease
AU - Ciccocioppo, Rachele
AU - Bernardo, Maria Ester
AU - Sgarella, Adele
AU - Maccario, Rita
AU - Avanzini, Maria Antonietta
AU - Ubezio, Cristina
AU - Minelli, Antonella
AU - Alvisi, Costanza
AU - Vanoli, Alessandro
AU - Calliada, Fabrizio
AU - Dionigi, Paolo
AU - Perotti, Cesare
AU - Locatelli, Franco
AU - Corazza, Gino Roberto
PY - 2011/6
Y1 - 2011/6
N2 - Objective: External fistulas represent a disabling manifestation of Crohn's disease with a difficult curability and a high relapse rate despite a large therapeutic armamentarium. Stem cell therapy is a novel and promising approach for treatment of chronic inflammatory conditions. We therefore investigated the feasibility, safety and efficacy of serial intrafistular injections of autologous bone marrow-derived mesenchymal stromal cells (MSCs) in the treatment of fistulising Crohn's disease. Patients and methods: We enrolled 12 consecutive outpatients (eight males, median age 32 years) refractory to or unsuitable for current available therapies. MSCs were isolated from bone marrow and expanded ex vivo to be used for both therapeutic and experimental purposes. Ten patients (two refused) received intrafistular MSC injections (median 4) scheduled every 4 weeks, and were monitored by surgical, MRI and endoscopic evaluation for 12 months afterwards. The feasibility of obtaining at least 50×106 MSCs from each patient, the appearance of adverse events, and the efficacy in terms of fistula healing and reduction of both Crohn's disease and perianal disease activity indexes were evaluated. In addition, the percentage of both mucosal and circulating regulatory T cells expressing FoxP3, and the ability of MSCs to influence mucosal T cell apoptosis were investigated. Results: MSC expansion was successful in all cases; sustained complete closure (seven cases) or incomplete closure (three cases) of fistula tracks with a parallel reduction of Crohn's disease and perianal disease activity indexes (p
AB - Objective: External fistulas represent a disabling manifestation of Crohn's disease with a difficult curability and a high relapse rate despite a large therapeutic armamentarium. Stem cell therapy is a novel and promising approach for treatment of chronic inflammatory conditions. We therefore investigated the feasibility, safety and efficacy of serial intrafistular injections of autologous bone marrow-derived mesenchymal stromal cells (MSCs) in the treatment of fistulising Crohn's disease. Patients and methods: We enrolled 12 consecutive outpatients (eight males, median age 32 years) refractory to or unsuitable for current available therapies. MSCs were isolated from bone marrow and expanded ex vivo to be used for both therapeutic and experimental purposes. Ten patients (two refused) received intrafistular MSC injections (median 4) scheduled every 4 weeks, and were monitored by surgical, MRI and endoscopic evaluation for 12 months afterwards. The feasibility of obtaining at least 50×106 MSCs from each patient, the appearance of adverse events, and the efficacy in terms of fistula healing and reduction of both Crohn's disease and perianal disease activity indexes were evaluated. In addition, the percentage of both mucosal and circulating regulatory T cells expressing FoxP3, and the ability of MSCs to influence mucosal T cell apoptosis were investigated. Results: MSC expansion was successful in all cases; sustained complete closure (seven cases) or incomplete closure (three cases) of fistula tracks with a parallel reduction of Crohn's disease and perianal disease activity indexes (p
UR - http://www.scopus.com/inward/record.url?scp=79955853222&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79955853222&partnerID=8YFLogxK
U2 - 10.1136/gut.2010.214841
DO - 10.1136/gut.2010.214841
M3 - Article
C2 - 21257987
AN - SCOPUS:79955853222
VL - 60
SP - 788
EP - 798
JO - Gut
JF - Gut
SN - 0017-5749
IS - 6
ER -